This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub

 

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Pratima
Chowdary, MD, FRCPath
Centre Director, Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom

Professor Chowdary is a Professor of Haemophilia and Haemostasis, Dept. of Haematology, University College of London (UCL) and Centre Director for the Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital. In addition, she is the Chairperson for the United Kingdom Haemophilia Centre Doctors Organisation and serves as co-director for the National Haemophilia Database.

Her clinical interests include the care of patients with Haemophilia and related bleeding disorders. Her primary research interests focus on strategies for personalised management of haemophilia,  novel therapies in haemophilia, acquired coagulopathy and bleeding. She is an active clinical researcher and is the chief investigator for several non-interventional and interventional studies, including UK EHL registry and UCL sponsored gene therapy studies in haemophilia A and B.

She has authored more than 100 peer-reviewed publications, including three textbook chapters. She is a chair and member of various national and international working parties, data safety monitoring boards, trial steering committees, national research peer review panels. She is also a  member of numerous professional societies, including the International Society on Thrombosis and Haemostasis, British Society of Haemostasis and Thrombosis, European Association of Allied Bleeding disorders and the World Federation of Haemophilia

Prof-Claude-Negrier-MD

Prof. Claude Negrier, MD

chairman of the Haematology Department at Louis Pradel University Hospital, Lyon, France


Claude Negrier was the chairman of the Haematology Department at Louis Pradel University Hospital in Lyon, France and director of the Haemophilia Comprehensive Care Centre at this institution. He is also Emeritus Professor of Haematology at the University of Lyon School of Medicine.

Dr. Negrier’s clinical and research interests include the evaluation of therapeutic modalities in patients with bleeding disorders, such as haemophilia, and particularly those who have developed an inhibitor. He is involved in preclinical research on the molecular and cellular investigation of factor VIII and IX deficiencies, phenotypic evaluation of the coagulation system, and pathophysiology of inherited platelet disorders. He has in addition a keen interest in the current and future preclinical and clinical recombinant technology, including non-replacement therapy and gene therapy for haemophilia.

Dr. Negrier is a member of several professional societies including the International Society on Thrombosis and Haemostasis, the American Society of Haematology, and the Word Federation of Haemophilia. He has authored or co-authored more than 270 peer-reviewed publications and book chapters and acts as a reviewer for different journals including Blood, Journal of Thrombosis and Haemostasis and Haemophilia, for which he is a member of the editorial board.

Dr. Negrier was the coordinator of the French national reference centre for haemophilia and other inherited bleeding disorders (2006-2021) and he served as the coordinator of the French Network on inherited bleeding disorders (2014-2021).


Read full bio
Dr. Davide Matino, MD

Dr. Davide Matino, MD

Assistant Professor of Medicine at McMaster University in Hamilton, Ontario, Canada


Dr. Davide Matino is an Assistant Professor of Medicine at McMaster University in Hamilton, Ontario, Canada. Dr. Matino obtained his medical degree at the University of Perugia and completed his residency training at the University of Rome “Tor Vergata”. He completed his Clinical Fellowship in Bleeding disorders at McMaster University where he also received his MSc in Health Research Methodology. Prior to joining faculty at McMaster University in 2020 he was working at the University of Perugia as Assistant Professor in the Department of Experimental Medicine, leading a research project focused on the study of the immune response to FVIII in haemophilia, funded by the Italian Ministry of Health. 

He is actively engaged in the care of patients with bleeding disorders and his research is focused on inhibitor development in haemophilia A, personalized-prophylaxis regimens in haemophilia, and the treatment of haemophilia patients with inhibitors. Dr. Matino contributes to education in the field of bleeding disorders locally, nationally and internationally.  He is an active clinical trial investigator involved in numerous trials in the field of thrombosis and haemostasis.

His work has received several awards and has been presented both nationally and internationally at the International Society for Thrombosis and Haemostasis, American Society of Haematology, and other scientific meetings. He is an active member of the Association of Haemophilia Clinic Directors of Canada (AHCDC) and a member of the Local Organising Committee for the Montreal 2023 International Society on Thrombosis and Haemostasis (ISTH) scientific meeting.


Read full bio